TX-MARY-KAY
Since 2021, Mary Kay Inc. has partnered with the Equal Rights Trust (ERT), an organization whose mission is to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. supported new research focused on understanding and addressing the discriminatory impacts of artificial intelligence (AI) and its impacts on gender equality, and the development of a new “equality by design approach.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215911706/en/
“Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. (Photo: Mary Kay Inc.)
The initiative culminated with the recent launch of a new set of legal standards – the Principles on Equality by Design in Algorithmic Decision-Making – developed by the Equal Rights Trust and endorsed by a group of leading international equality organizations. The Principles elaborate why national governments and businesses must adopt such an approach and provide detailed guidance for its implementation.
Jim Fitzgerald, Director of Equal Rights Trust, just released an article highlighting the rapid advancements and transformative potential of artificial intelligence while also warning about adverse impacts and discriminatory threats unregulated algorithmic systems could pose.
- Read Jim Fitzgerald’s article titled Equality by Design: A Model for Managing Discriminatory Risks of AI here.
Statements from Jim Fitzgerald, Director of Equal Rights Trust and Melinda Foster Sellers, Chief People Officer at Mary Kay Inc., can be found below:
- “Over the last three years, Mary Kay has supported our research, analysis, and consultation on algorithmic discrimination, and enabled us to develop the Principles on Equality by Design,” said Jim Fitzgerald, Director of the Equal Rights Trust. “Now, Mary Kay is working with us as we move into the next phase: a collaborative effort to develop practical guidance for business on how to adopt the equality by design approach. In doing so, it is taking the next step in a journey which started with strong internal equality and non-discrimination policies, moved to collaboration with and support for us and other actors in this field, and is now focused on incubating and piloting best practice. In this journey, Mary Kay is helping to model how businesses can play an active role in developing improved approaches to eliminating discrimination and advancing equality.”
- "At Mary Kay, we recognize the profound impact that AI has on shaping the future of business and society,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. “Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers. This partnership reflects our enduring mission to empower women and promote equality in every sphere."
About Equal Rights Trust
The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this, it works in partnership to provide expert support to those on the frontlines of the fight against discrimination, enabling them to press for the development, adoption, and implementation of equality law, and to use the law effectively. Since 2007, the Trust has supported equality activists in more than 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly known as Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215911706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom